The bear case for NASH companies (scan up to see start of thread):
6. Payers may prevent this from being a massive market. They are aware of what NASH could do to their P&Ls. Will require lifestyle changes, drug response monitoring, etc. which becomes an issue given prior point around asymptomatic pts not wanting to deal with all that
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.